(37 days)
The ACHIEVA , INTERA and PANORAMA 1.0T Release 2-series are magnetic resonance diagnostic devices that produce cross-sectional images, spectroscopy images and/or spectra in any orientation of the internal structure of the whole body. These images when interpreted by a trained physician, yield information that may assist in diagnosis.
The ACHIEVA , INTERA and PANORAMA 1.0T Release 2-series are the successor of the predicate devices ACHIEVA, INTERA and PANORAMA 1.0T release 1-series. The Release 2-series introduces the new functionalities:
- Fiber Tracking .
Diffusion Tensor Imaging (DTI) extends the functionality of Diffusion Weighted Imaging (DWI) to measure the directional dependence of the diffusion coefficient in tissue. With Fiber Tracking the directional dependency can be used to visualize the white matter structure in the brain. - Smart Scan .
SmartScan enables automatic planning of geometries and acquisition. When needed the user can control and confirm the automatically planned acquisition. The ExamCard provides the fully automated process of data acquisition.
Regional Perfusion Imaging (Arterial Spin Labeling)
Regional Perfusion Imaging with Arterial Spin Labeling provides a noninvasive acquisition method for selectively mapping of the flow territories and to determine the regional perfusion in the human brain. - kt-BLAST and kt-SENSE. .
Kt-BLAST (Broad-use Linear Acquisition Speed-up Technique) reduces scan time of dynamic and multi-phase studies by also using k-space data from other dynamics / phases. Kt-SENSE combines kt-BLAST with SENSE parallel imaging. Kt-blast and kt-SENSE can be applied to reduce scan time or improve temporal resolution of dynamic or multi-phase studies.
The ACHIEVA, INTERA and PANORAMA 1.0T Release 2-series are the successors of the predicate devices ACHIEVA , INTERA and PANORAMA 1.0T Release 1-series. The design of the Release 2-series are based on the same software platform and hardware technology as their predicate devices.
The provided text describes a 510(k) submission for Philips Medical Systems' ACHIEVA, INTERA, and PANORAMA 1.0T Release 2-series of Magnetic Resonance Diagnostic Devices (MRDD). However, the document does not contain specific information regarding acceptance criteria, device performance studies, sample sizes, expert qualifications, or ground truth establishment.
Instead, the submission focuses on demonstrating substantial equivalence to their predicate devices (Release 1-series, K043147, K041602). The key argument for substantial equivalence is that the Release 2-series introduces new functionalities (Fiber Tracking, Smart Scan, Regional Perfusion Imaging, kt-BLAST, kt-SENSE) but does not induce any other risks than already indicated for their predicate devices with the same safety and effectiveness. This implies that the safety and effectiveness of the new features are considered to be within the established parameters of the predicate devices.
Therefore, I cannot populate the requested table or answer the specific questions about the study that proves the device meets acceptance criteria, as this information is not present in the provided document. The document essentially states that because the new device is a technological update that does not introduce new safety or effectiveness risks compared to its predecessor, specific new performance studies for acceptance criteria are not detailed in this submission.
{0}------------------------------------------------
Image /page/0/Picture/0 description: The image shows a handwritten string of characters. The characters appear to be a combination of letters and numbers. The string reads 'Ko52078'. The characters are written in a dark ink on a white background.
XJR-148-6901/bf
SEP = 7 2005
Page 1 of 2
510(k) SUMMARY OF SAFETY AND EFFECTIVENESS
The following information is being submitted in accordance with the requirements of 21 CFR 807.92.
General information
| Company Name: | Philips Medical Systems Nederland BVAttn: Budhy Fredriksz, MR Q & RA |
|---|---|
| Address: | Veenpluis 4-65684 PC Best, Netherlands, |
| Registration No.: | 300376277 |
| Contact person: | Lynn HarmerManager, Regulatory SubmissionsTel: (425) 487-7312Fax: (425) 487-8666Lynn.Harmer@Philips.com |
| Date Prepared: | 26 July 2005 |
| Device (Trade) Name: | ACHIEVA , INTERA and PANORAMA 1.0T. |
| Classification Name: | Magnetic Resonance Diagnostic Device (MRDD) |
| Regulatory Number: | 892.1000 |
| Classification: | Class II |
| Product code: | LNH |
| Performance standards: | NEMA voluntary standards, FDA MR DiagnosticDevice Guidance, UL and IEC 60601 appropriate safetystandards and/or draft standards are used. |
Predicate Device(s):
The ACHIEVA , INTERA and PANORAMA 1.0T Release 2-series are the successor of the predicate devices ACHIEVA, INTERA and PANORAMA 1.0T release 1-series. (FDA references K043147, K043147 & K041602).
Indications for use:
The ACHIEVA , INTERA and PANORAMA 1.0T Release 2-series are magnetic resonance diagnostic devices that produce cross-sectional images, spectroscopy images and/or spectra in any orientation of the internal structure of the whole body. These images when interpreted by a trained physician, yield information that may assist in diagnosis.
{1}------------------------------------------------
Device description:
The ACHIEVA , INTERA and PANORAMA 1.0T Release 2-series are the successor of the predicate devices ACHIEVA, INTERA and PANORAMA 1.0T release 1-series. The Release 2-series introduces the new functionalities:
-
Fiber Tracking .
Diffusion Tensor Imaging (DTI) extends the functionality of Diffusion Weighted Imaging (DWI) to measure the directional dependence of the diffusion coefficient in tissue. With Fiber Tracking the directional dependency can be used to visualize the white matter structure in the brain. -
Smart Scan .
SmartScan enables automatic planning of geometries and acquisition. When needed the user can control and confirm the automatically planned acquisition. The ExamCard provides the fully automated process of data acquisition.
Regional Perfusion Imaging (Arterial Spin Labeling)
Regional Perfusion Imaging with Arterial Spin Labeling provides a noninvasive acquisition method for selectively mapping of the flow territories and to determine the regional perfusion in the human brain.
- kt-BLAST and kt-SENSE. .
Kt-BLAST (Broad-use Linear Acquisition Speed-up Technique) reduces scan time of dynamic and multi-phase studies by also using k-space data from other dynamics / phases. Kt-SENSE combines kt-BLAST with SENSE parallel imaging. Kt-blast and kt-SENSE can be applied to reduce scan time or improve temporal resolution of dynamic or multi-phase studies.
The ACHIEVA, INTERA and PANORAMA 1.0T Release 2-series are the successors of the predicate devices ACHIEVA , INTERA and PANORAMA 1.0T Release 1-series. The design of the Release 2-series are based on the same software platform and hardware technology as their predicate devices.
General Safety and Effectiveness
The ACHIEVA, INTERA and PANORAMA 1.0T Release 2-series do not induce any other risks than already indicated for their predicate devices with the same safety and effectiveness.
Substantial Equivalence
It is the opinion of Philips Medical Systems that the Philips ACHIEVA, INTERA and PANORAMA 1.0T Release 2-series are substantially equivalent to their predicate devices Release 1-series.
End
{2}------------------------------------------------
Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo is circular and contains the department's name around the perimeter. In the center is an abstract symbol that resembles an eagle or bird in flight, composed of three curved lines.
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
Philips Medical Systems Nederland BV % Ms. Lynn Harmer Manager, Regulatory Submissions Philips Medical Systems North America 22100 Bothell Everett Highway BOTHELL WA 98021-8431
Re: K052078
Trade/Device Name: Achieva, Intera & Panorama 1.0T Release 2-series Regulation Number: 21 CFR 892.1000 Regulation Name: Magnetic resonance diagnostic device Regulatory Class: II Product Code: LNH
Dated: July 28, 2005 Received: August 1, 2005
Dear Ms. Harmer:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality of your (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
SEP - 7 2005
{3}------------------------------------------------
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally promation would be device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at one of the following numbers, based on the regulation number at the top of this letter:
| 21 CFR 876.xxxx | (Gastroenterology/Renal/Urology) | 240-276-0115 |
|---|---|---|
| 21 CFR 884.xxxx | (Obstetrics/Gynecology) | 240-276-0115 |
| 21 CFR 892.xxxx | (Radiology) | 240-276-0120 |
| Other | 240-276-0100 |
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html
Sincerely yours,
Nancy C. Hogdon
Nancy C. Brogdon Director, Division of Reproductive, Abdominal, and Radiological Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{4}------------------------------------------------
510(k) Number (if known):
Korzu78
Device Name :
ACHIEVA, INTERA & PANORAMA 1.0T Release 2-series.
Indication For Use :
The ACHIEVA , INTERA and PANORAMA 1.0T Release 2-series are magnetic resonance diagnostic devices that produce cross-sectional images, spectroscopy images and/or spectra in any orientation of the internal structure of the whole body. These images when interpreted by a trained physician, yield information that may assist in diagnosis.
Prescription Use × (Per 21 CFR 801.109)
OR Over-The-Counter Use _________________________________________________________________________________________________________________________________________________________
( PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Daniel P. Lyons
(Division Sign-Off)
Division of Reproductive, and Radiological Devices 510(k) Number
§ 892.1000 Magnetic resonance diagnostic device.
(a)
Identification. A magnetic resonance diagnostic device is intended for general diagnostic use to present images which reflect the spatial distribution and/or magnetic resonance spectra which reflect frequency and distribution of nuclei exhibiting nuclear magnetic resonance. Other physical parameters derived from the images and/or spectra may also be produced. The device includes hydrogen-1 (proton) imaging, sodium-23 imaging, hydrogen-1 spectroscopy, phosphorus-31 spectroscopy, and chemical shift imaging (preserving simultaneous frequency and spatial information).(b)
Classification. Class II (special controls). A magnetic resonance imaging disposable kit intended for use with a magnetic resonance diagnostic device only is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 892.9.